This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

REPORT OF STUDY BY ARMY, NAVY, AIR FORCE MOTION SICKNESS TEAM

J Am Med Assoc. 1956;160(9):755-760.

Abstract
• Twenty-six compounds have been compared with a placebo as to effectiveness in preventing seasickness in 16,920 soldiers and airmen crossing the Atlantic. The most significant benefit was obtained by using 50 gm. of meclizine once or thrice daily, 50 mg. of cyclizine thrice daily, or 25 mg. promethazine thrice daily.

Four other drugs were demonstrated for the first time to be effective against seasickness. Earlier reports of the effectiveness of scopolamine hydrobromide were verified as to single doses, but on continued use it gave the most distressing sideeffects of all the prophylactics used. For continued use, meclizine was the most satisfactory.

Motion sickness was twice as frequent in those who had had it before as in those with no previous history of it. It was less frequent in the older men, in those who had crossed before, and in those quartered midship.

Footnotes
Herman I. Chinn, Ph.D., School of Aviation Medicine, Randolph Field, Texas, was principal investigator. Other members of the team were S. Bayne-Jones, M.D., and C. S. Gersoni, Ph.D., Office of Surgeon General, U. S. Army, Washington, D. C.; A. C. Henderson and H. E. Zeransky, Army Medical Research Laboratory, Fort Knox, Ky.; E. H. Schein, Ph.D., Walter Reed Army Medical Center, Washington, D. C.; H. T. Karsner, M.D., R. A. Phillips, M.D., and O. D. Yarbrough, M.D., Bureau of Medicine and Surgery Department of the Navy, Washington, D. C.; G. J. Duffner, M.D., and J. L. Kinsey, M.D., Naval Medical Research Laboratory, New London, Conn.; R. S. Melton, Ph.D., and R. B. Voas, Ph.D., U. S. Naval School of Aviation Medicine, Pensacola, Fla.; M. Jones, Ph.D., Office of Naval Research, Chicago; C. H. Maag, Ph.D., and R. Trumbull, Ph.D., Office of Naval Research, Washington, D. C.; C. C. Shaw, M.D., Philadelphia Navy Shipyard, Philadelphia; P. K. Smith, Ph.D., George Washington University School of Medicine, Washington, D. C.; and R. O. Bauer, M.D., H. M. Sweeney, Ph.D., and N. Weiner, M.D., U. S. Air Force School of Aviation Medicine, Randolph Field, Texas.

This work is not to be construed as necessarily reflecting the views of the Department of Defense.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Meclizine and Placebo in Treating Vertigo of Vestibular Origin: Relative Efficacy in a Double-Blind Study
Cohen and deJong
Arch Neurol 1972;27:129-135.
ABSTRACT  

Clinical Effectiveness of Anti-motion-Sickness Drugs: Computer Review of the Literature
Wood et al.
JAMA 1966;198:1155-1158.
ABSTRACT  

Prevention of Airsickness with Meprobamate
Franks et al.
JAMA 1962;181:263-264.
ABSTRACT